|Systematic (IUPAC) name|
|Molar mass||323.818 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
Renzapride is a gastroprokinetic agent and antiemetic which acts as a full 5-HT4 full agonist and 5-HT3 antagonist. It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors, though it is unlikely that these properties contribute to its therapeutic effects.
Renzapride was being developed by Alizyme plc of the United Kingdom.
Renzapride was being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It is also potentially effective for irritable bowel syndrome with alternating stool pattern (IBS-A). It is being developed by Alizyme plc of the United Kingdom.
As of 23 April 2008, Alizyme ceased all development of renzapride, after a Phase III trial in the U.S. did not show enough efficacy over placebo to justify further development.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|45px||This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it.|
- Meyers NL, Hickling RI. (2008). "Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome". Drugs R D. 9 (1): 37–63. PMID 18095752.
- Camilleri M., McKinzie S., Fox J., Foxx-Orenstein A., Burton D., Thomforde G., Baxter K. and Zinsmeister A. R. (2004). "Effect of Renzapride on Transit in Constipation-Predominant Irritable Bowel Syndrome", Clin. Gastroent. and Hepatology; 2:895-904
- "Results from Renzapride" (Press release). Alizyme plc. 23 April 2008. http://www.alizyme.com/alizyme/media/press/show.jsp?ref=128. Retrieved 7 May 2009.